 | |
| Names | |
|---|---|
| IUPAC name [(3aR,8bS)-3,4,8b-Trimethyl-2,3a-dihydro-1H-pyrrolo[2,3-b]indol-7-yl] 3,4-dihydro-1H-isoquinoline-2-carboxylate | |
| Identifiers | |
3D model (JSmol) | |
| ChEBI | |
| ChEMBL | |
| ChemSpider | |
| KEGG | |
| UNII | |
| |
| |
| Properties | |
| C23H27N3O2 | |
| Molar mass | 377.488 g·mol−1 |
Except where otherwise noted, data are given for materials in theirstandard state (at 25 °C [77 °F], 100 kPa). | |
Quilostigmine, also known asNXX-066, is anacetylcholinesterase inhibitor. Its structure is related to that ofphysostigmine,[1] another acetylcholinesterase (AChE) inhibitor.
Quilostigmine displays inhibition of the AChE enzyme with anIC50 value of 0.148 µM.[2]
Quilostigmine was initially studied by AstraZeneca for the treatment ofAlzheimer's disease;[3][4] however, the drug appears to have been discontinued,[5] reaching a maximum trial phase of two.[6]
